✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Reviewed by Sophie Carter, MPharm — last reviewed 11 May 2026
Quick Answer — Minoxidil vs Finasteride
Minoxidil and finasteride are the two most evidence-backed hair loss treatments — and they work through completely different mechanisms. Finasteride blocks the production of DHT (the hormone that shrinks follicles in androgenetic alopecia). Minoxidil prolongs the hair growth phase and improves follicular blood supply but does nothing about DHT. The combination consistently outperforms either agent alone. Most dermatologists recommend both for men with moderate-to-severe androgenetic alopecia.
How they work — different targets
Finasteride inhibits 5-alpha-reductase type II, the enzyme that converts testosterone to dihydrotestosterone (DHT). In genetically susceptible men, DHT binds to androgen receptors in scalp follicles, triggering progressive miniaturisation. Blocking DHT production at the source — reducing serum DHT by ~70% at 1 mg — stops this process and allows miniaturised follicles to partially recover. Finasteride is addressing the cause of androgenetic alopecia.
Minoxidil is a potassium-channel opener originally developed as an antihypertensive. Applied topically, it prolongs the anagen (growth) phase of the hair cycle, shifts follicles from telogen (rest) back into active growth, and increases perifollicular blood flow and nutrient delivery. Minoxidil does not affect DHT. It is treating the symptoms of follicular stress without addressing the hormonal cause.
Head-to-head: which works better?
| Factor | Finasteride 1 mg | Minoxidil 5% topical |
|---|---|---|
| Mechanism | Hormonal (blocks DHT) | Vascular / anagen prolongation |
| Hair count improvement at 12 months | +9–10% in clinical trials (vertex) | +8–14% depending on formulation |
| Effectiveness at hairline | Moderate | Limited (frontal less responsive) |
| Works after stopping? | No — loss resumes within 6–12 months | No — gains lost within 3–4 months |
| Suitable for women? | No (teratogenic) | Yes (2% formulation for women) |
| Route | Oral (daily tablet) | Topical (scalp, 1–2×/day) |
Research Spotlight — Combination therapy
A 2015 randomised trial (Hu et al., J Eur Acad Dermatol Venereol) enrolled 450 men with AGA and found that combination finasteride 1 mg + minoxidil 5% topical significantly outperformed either monotherapy at 12 months in hair count, scalp coverage score, and patient satisfaction rating. At 12 months: combination 35% improvement vs finasteride alone 21% vs minoxidil alone 19%. The combination is now standard-of-care in most dermatology guidelines for moderate-to-severe AGA.
The practical case for each
Finasteride alone makes sense if:
- You want a single daily oral tablet with no topical routine
- Hair loss is primarily DHT-driven miniaturisation at vertex/crown
- You want disease-modifying treatment, not just symptomatic management
Minoxidil alone makes sense if:
- You are female (finasteride is contraindicated; minoxidil 2% is first-line for women)
- You want to avoid finasteride’s hormonal side effects
- Scalp density improvement is the priority over hairline preservation
Both together makes sense if:
- You have moderate-to-severe AGA
- You’ve tried one alone and had partial results
- You want maximum evidence-backed protection with acceptable tolerability
Side effects compared
Finasteride: sexual side effects in 2–4% in clinical trials (libido reduction, ED, ejaculatory changes); PSA halving (inform your GP); teratogenic — pregnant partners must not handle crushed tablets. See our finasteride 1 mg vs 5 mg guide for full detail.
Minoxidil: initial shedding in first 4–6 weeks (telogen hair shedding as anagen phase is induced — alarming but temporary); scalp irritation, dryness, itching (2–5%); systemic effects rare with topical use but include headache and tachycardia if accidentally ingested; hypertrichosis (facial hair growth) in women.
Products available at MedsBase
- Finpecia 1 mg (Cipla) — WHO-GMP finasteride tablet, the standard generic for AGA
- Tugain Foam 5% (Sun Pharma) — minoxidil foam, less dripping and residue than solution, once-daily application
- Tugain Solution 5% — minoxidil solution, twice-daily application
- Mintop Lotion — minoxidil lotion for scalp
- Hair Loss Stack — Finasteride + Minoxidil Foam bundled
The “shedding” phase — both treatments cause it
Both finasteride and minoxidil can trigger an initial shedding phase in the first 4–12 weeks. This is not failure — it is the follicular cycle synchronising and miniaturised hairs making way for terminal growth. Most users who persist past this phase see their best results at 12 months. The combination approach can sometimes produce a more pronounced early shed because both mechanisms are active simultaneously. This is temporary.
Medical Disclaimer
Finasteride is a prescription medicine contraindicated in women of childbearing potential. Minoxidil is available over-the-counter in most markets but has cardiovascular contraindications at systemic doses. This guide is educational — consult a dermatologist or GP before starting combination therapy, especially if you have cardiovascular disease.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.